Antiviral activity of novel oseltamivir derivatives against some influenza virus strains

• Authors: Janusz Kocik , Marcin Kołodziej , Justyna Joniec , Magdalena Kwiatek , Michał Bartoszcze
• Languages of publication: EN

Abstracts

EN

The aim of this study was to investigate the in vitro cytotoxicity of oseltamivir derivatives and determine their activity against A/H1N1/PR/8/34 and A/H3N2/HongKong/8/68 - strains of influenza virus. Antiviral activity of these compounds was determined by using two methods. MTT staining was used to assess the viability of MDCK cells infected with influenza viruses and treated with various concentrations of drugs. In parallel, the effect of drugs on viral replication was assessed using the hemagglutination test. The most toxic compounds were: OS-64, OS-35, OS-29, OS-27 and OS-25, whereas OS-11, OS-20 and OS-23 were the least toxic ones. Statistically significant antiviral effect at a higher virus dose was shown by compounds: OS-11, OS-20, OS-27, OS-35, and OS-64. H3N2 virus was sensitive to 10-times lower concentrations of OS-11 and OS-35 than H1N1. At a lower infection dose, the antiviral activity was observed for OS-11, OS 27, OS-35 and OS-20. OS-64 turned out to be effective only at a high concentration. OS-23 showed no antiviral effect.

Keywords

EN

influenza virus; neuraminidase inhibitors; oseltamivir; antiviral activity; cytotoxicity

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2014
• Volume: 61
• Issue: 3
• Pages: 509-513

Dates

published

2014

received

2014-08-26

revised

2014-08-27

accepted

2014-08-27

(unknown)

2014-09-12

Contributors

author

Janusz Kocik

• Military Institute of Hygiene and Epidemiology, Warsaw, Poland

author

Marcin Kołodziej

• Biological Threats Identification and Countermeasure Center of MIHE, Puławy, Poland

author

Justyna Joniec

• Biological Threats Identification and Countermeasure Center of MIHE, Puławy, Poland

author

Magdalena Kwiatek

• Biological Threats Identification and Countermeasure Center of MIHE, Puławy, Poland

author

Michał Bartoszcze

• Biological Threats Identification and Countermeasure Center of MIHE, Puławy, Poland

References

• Barnett JM, Cadman A, Gor D, Dempsey M, Walters M, Candlin A, Tisdale M, Morley PJ, Owens IJ, Fenton RJ, Lewis AP, Claas EC, Rimmelzwaan GF, de Groot R, Osterhaus AD (2000) Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 44: 78-87.
• Berhane Y, Kehler H, Handel K, Hisanaga T, Xu W, Ojkic D, Pasick J (2012) Molecular and antigenic characterization of reassortant H3N2 - viruses from turkeys with a unique constellation of pandemic H1N1 Internal Genes. PLoS ONE 7: e32858.
• Davies BE (2010) Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 65 (Suppl 2): ii5-10.
• de Jong MD, Thanh TT, Truong HK, Hien VM, Smith GJD, Chau NV, Cam BV, Qui PT, Ha DQ, Guan Y, Malik Peiris JS, Hien TT, Farrar J (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
• Durrant JD, McCammon JA (2010) Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. Comput Biol Chem 34: 97-105.
• Earhart KC, Elsayed NM, Saad MD, Gubareva LV, Nayel A, Deyde VM, Abdelsattar A, Abdelghani AS, Boynton BR, Mansour MM, Essmat HM, Klimov A, Shuck-Lee D, Monteville MR, Tjaden JA (2009) Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health 2: 74-80.
• Fukushi M, Yamashita M, Miyoshi-Akiyama T, Kubo S, Yamamoto K, Kudo K (2012) Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 virus. PLoS ONE 7: e42419.
• Galabov AS, Simeonova L, Gegova G (2006) Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A(H3N2) influenza virus in mice. Antivir Chem Chemother 17: 251-258.
• Ghedin E, Holmes EC, DePasse JV, Pinilla LT, Fitch A, Hamelin ME, Papenburg J, Boivin G (2012) Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. J Infect Dis 206: 1504-1511.
• Govorkova EA, Fang HB, Tan M, Webster RG (2004) Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK Cells. Antimicrob Agents Chemother 48: 4855-4863.
• Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG (2001) Comparison of efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 45: 2723-2732.
• Gubareva LV, Webster RG, Hayden FG (2001) Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45: 3403-3408.
• Hayden F (2009) Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48 (Suppl 1): S3-S13.
• Hayden F, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J, Macken C, Hampson A, Webster RG, Amyard M, Zambon M (2005) Neuraminidase Inhibitor Susceptibility Network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 10: 873-877.
• Hedlund M, Larson JL, Fang F (2010) Antiviral strategies for pandemic and seasonal influenza. Viruses 2: 1766-1781.
• ---
• ---
• Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, Guigon A, Harrower B, Kei IP, Kok T, Lin C, McPhie K, Mohd A, Olveda R, Panayotou T, Rawlinson W, Scott L, Smith D, D'Souza H, Komadina N, Shaw R, Kelso A, Barr IG (2009a) Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 83: 90-93.
• Hurt AC, Holien JK, Parker MW, Barr IG (2009b) Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 69: 2523-2531.
• Hussain Basha S, Prasad RN (2012) In-Silico screening of Pleconaril and its novel substituted derivatives with Neuraminidase of H1N1 Influenza strain. BMC Res Notes 5: 105.
• Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M (2010) Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor,Shows Superior Anti-Influenza Virus Activity after a Single Administration. Antimicrob Agents Chemother 54: 1256-1264.
• Kwiatek M, Kocik J, Bartoszcze M (2009) The substances active against influenza virus. Possibilities and prospects of application. Przegl Epidemiol 63: 487-494 (in Polish).
• Levi R, Beeor-Tzahar T, Arnon R (1995) Microculture virus titration - a simple colourimetric assay for influenza virus titration. J Virol Methods 52: 55-64.
• Li Y, Zhou B, Wang R (2009) Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1. J Mol Graphics Model 28: 203-219.
• Machała MK, Brydak LB (2006) Various sides of influenza, part I - Structure, replication, changeability of influenza viruses, clinical course of the disease, immunological response and laboratory diagnostics. Pol Merkur Lekarski 21:(123), 270 (in Polish).
• Mehrbod P, Motamed N, Tabatabaian M, Soleimani Estyar R, Amini E, Shahidi M, Kheiri MT (2009) In vitro antiviral of 'Nanosilver' on influenza virus. DARU 17: 88-93.
• Meijer A, Jonges M, van Beek P, Swaan CM, Osterhaus AD, Daniels RS, Hurt AC, Koopmans MP (2012) Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012. Euro Surveill 17: pii: 20266.
• Mitrasinovic PM (2009) On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Biophys Chem 140: 35-38.
• Ng S, Cowling BJ, Fang VJ, Chan KH, Ip DK, Cheng CK, Uyeki TM, Houck PM, Malik Peiris JS, Leung GM (2010) Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis 50: 707-714.
• Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, Blair PJ, de Jong MD, Prichard MN, Went GT (2010) Triple combination of Amantadine, Ribavirin, and Oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. Antimicrob Agents Chemother 53: 4115-4126.
• Nie LD, Shi XX (2009) A novel asymmetric synthesis of oseltamivir phosphate (Tamiflu) from (-)-shikimic acid. Tetrahedron: Asymmetry 20: 124-129.
• Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV (2010) Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2: 2269-2289.
• Park JW, Jo WH (2010) Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus. Eur J Med Chem 45: 536-541.
• Payungporn S, Poomipak W, Makkoch J, Rianthavorn P, Theamboonlers A, Poovorawan Y (2011) Detection of oseltamivir sensitive/resistant strains of pandemic influenza A virus (H1N1) from patients admitted to hospitals in Thailand. J Virol Methods 177: 133-139.
• Rungrotmongkol T, Frecer V, De-Eknamkul W, Hannongbua S, Miertus S (2009) Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Antiviral Res 82: 51-58.
• Saito R, Sakai T, Sato I, Sano Y, Oshitani H, Sato M, Suzuki H (2003) Frequency of amantadine-resistant influenza a viruses during Two seasons featuring cocirculation of H1N1 and H3N2. J Clin Microbiol 41: 2164-2165.
• Satoh N, Akiba T, Yokoshima S, Fukuyama T (2009) A practical synthesis of (-)-oseltamivir. Tetrahedron 65: 3239-3245.
• Sheu TG, Deyde VM, Okomo-Adhiambo M, Gerten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV (2008) Surveillance for neuraminidase inhibitor resistance among human Influenza A and B viruses circulating worldwide from 2004-2008. Antimicrob Agents Chemother 52: 3284-3292.
• Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, Hou W, Cheng L, Xiao H, Yang Z (2007) Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 152: 1447-1455.
• Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD (2009) Effects of Double Combinations of Amantadine, Oseltamivir, and Ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 53: 2120-2128.
• Smee DF, Hurst BL, Wong MH, Bailey KW, Tarbet EB, Morrey JD, Furuta Y (2010) Effects of the combination of Favipiravir (T-705) and Oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 54: 126-133.
• Smee DF, Sidwell RW (2002) Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs 11: 859-869.
• Triana-Baltzer GB, Gubareva LV, Klimov AI, Wurtman DF, Moss RB, Hedlund M, Larson JL, Belshe RB, Fang F (2009) Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS ONE 4: e7838.
• Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H., Jiang H, Gao GF (2011) Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog 7: e1002249.
• Wang SQ, Cheng XC, Dong WL, Wang RL, Chou KC (2010) Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus. Biochem Biophysi Res Commun 401: 188-191.
• Yamanaka T, Tsujimura K, Kondo T, Matsumura T (2006) In vitro efficacies of Oseltamivir carboxylate and Zanamivir against equine influenza A viruses. J Vet Med Sci 68: 405-408.